Nephrology and urology: clinical-trial pipeline
32,894 nephrology and urology trials are in ClinicalTrials.gov and the EU CTIS portal; 7,678 are not yet finished and 647 of those are in phase 2/3 or 3. Source: Arcadium Data, data as of .
Open trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 4,604 |
| Phase 2 | 1,089 |
| Phase 3 | 543 |
| Phase 1 | 510 |
| Phase 1/2 | 353 |
| Phase 4 | 340 |
| Early phase 1 | 135 |
| Phase 2/3 | 104 |
Sponsors with the most open trials
Recently changed open trials
| Registry id | Title | Sponsor | Phase | Status | Countries |
|---|---|---|---|---|---|
| NCT06307431 | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). | Merck Sharp & Dohme LLC | Phase 2 | Active, not recruiting | Argentina, Australia, Canada, Chile +9 |
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castra… | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Australia, Brazil, Canada, Chile +34 |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Argentina, Austria, Australia, Brazil +31 |
| NCT06120491 | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physicia… | AstraZeneca | Phase 3 | Not yet recruiting | Austria, Australia, Belgium, Brazil +21 |
| NCT06087835 | Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin… | AstraZeneca | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Bulgaria +25 |
| NCT05817903 | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients | Consorzio Oncotech | Phase 2 | Recruiting | Spain, Italy |
| NCT05316155 | Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | Janssen Research & Development, LLC | Phase 1/2 | Active, not recruiting | Canada, Germany, Spain, Israel +4 |
| NCT05196035 | A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into,… | Bayer | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +27 |
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | IDEAYA Biosciences | Phase 1 | Active, not recruiting | Australia, Germany, Spain, France +3 |
| NCT04691804 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abir… | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 | Active, not recruiting | Australia, Belgium, China, Czechia +9 |
| NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cel… | Merck Sharp & Dohme LLC | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +21 |
| 2023-509235-39-00 | Cytisine in prolonged dosage versus Nicotine Replacement Therapy in nicotine-dependent patients with Chronic… | Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy | Phase 4 | Recruiting | Poland |
| 2023-508335-31-00 | ElucidatiNg Immunosuppressant pharmacokinetic variabilities by investigating Gut Microbiota modulations After… | Universite Catholique de Louvain | Phase 4 | Recruiting | Belgium |
| NCT06565247 | Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation | Region Västerbotten | Phase 3 | Recruiting | Sweden |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety,… | Lumara Bio Oncologics GmbH | Phase 1/2 | Recruiting | Australia, Belgium, France |
| NCT05457283 | A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an AC… | Bayer | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +27 |
| NCT06496581 | Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) | UNICANCER | Phase 3 | Recruiting | Belgium, Spain, France, Ireland +2 |
| NCT06305767 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V94… | Merck Sharp & Dohme LLC | Phase 1/2 | Active, not recruiting | Australia, Canada, Chile, Colombia +11 |
| NCT05714202 | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guér… | Janssen Research & Development, LLC | Phase 3 | Active, not recruiting | Argentina, Australia, Belgium, Brazil +17 |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | Exelixis | Phase 1 | Recruiting | Austria, Australia, Belgium, Switzerland +9 |
All areas: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Nephrology and urology clinical trials: 7,678 open, 647 in phase 3", https://arcadiumdata.io/clinical-trials/area/nephrology-urology/, data as of 2026-10-25.